Biacetyl monoxime

Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca2+ release[1][2][3].

Product Specifications

CAS Number

[57-71-6]

Product Name Alternative

Diacetyl monoxime; DAM

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Myosin; Na+/K+ ATPase

Type

Reference compound

Related Pathways

Cytoskeleton; Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/biacetyl-monoxime.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C/C(C(C)=O)=N\O

Molecular Formula

C4H7NO2

Molecular Weight

101.10

Precautions

H302, H315, H319, H335

References & Citations

[1]Kohsuke Hashimoto, et al. The myosin ATPase inhibitor, 2,3-butanedione 2-monoxime, prevents protein secretion by the basidiomycete Coprinopsis cinerea. Biotechnol Lett. 2011 Apr;33 (4) :769-75.|[2]R M Phillips, et al. 2,3-Butanedione 2-monoxime (BDM) induces calcium release from canine cardiac sarcoplasmic reticulum. Biochem Biophys Res Commun. 1996 Dec 4;229 (1) :154-7. |[3]Ostap EM. 2,3-Butanedione monoxime (BDM) as a myosin inhibitor. J Muscle Res Cell Motil. 2002;23 (4) :305-8.|[4]Xiao YF, et al. Effects of 2,3-butanedione monoxime on blood pressure, myocardial Ca2+ currents, and action potentials of rats. Am J Hypertens. 1995 Dec;8 (12 Pt 1) :1232-40.|[5]Brightman T, et al. 2,3-Butanedione monoxime protects mice against the convulsant effect of picrotoxin by facilitating GABA-activated currents. Brain Res. 1995 Apr 24;678 (1-2) :110-6.